Facial hyperpigmentation during imatinib therapy for gastrointestinal stromal tumor

Therapie. 2014 May-Jun;69(3):245-7. doi: 10.2515/therapie/2014018. Epub 2014 Jun 18.

Authors

Imene Hamza¹, Emna Gaies², Sarrah Kastalli², Riadh Daghfous², Sihem El Aidli²

Affiliations

¹ Centre national de Pharmacovigilance de Tunis, Tunisie.
² Centre national de Pharmacovigilance de Tunis, Tunisie - Université de Tunis El Manar, Faculté de Médecine de Tunis, Tunis, Tunisie.

PMID: 24934821
DOI: 10.2515/therapie/2014018

Abstract

We report a rare case of facial hyperpigmentation during imatinib therapy for a gastrointestinal stromal tumor.

© 2014 Société Française de Pharmacologie et de Thérapeutique.

Publication types

Case Reports

MeSH terms

Adult
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects*
Antineoplastic Agents / therapeutic use
Benzamides / administration & dosage
Benzamides / adverse effects*
Benzamides / therapeutic use
Facial Dermatoses / chemically induced*
Female
Gastrointestinal Neoplasms / drug therapy
Gastrointestinal Neoplasms / pathology
Gastrointestinal Stromal Tumors / drug therapy
Gastrointestinal Stromal Tumors / pathology
Humans
Hyperpigmentation / chemically induced*
Imatinib Mesylate
Piperazines / administration & dosage
Piperazines / adverse effects*
Piperazines / therapeutic use
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / adverse effects
Protein Kinase Inhibitors / therapeutic use
Pyrimidines / administration & dosage
Pyrimidines / adverse effects*
Pyrimidines / therapeutic use

Substances

Antineoplastic Agents
Benzamides
Piperazines
Protein Kinase Inhibitors
Pyrimidines
Imatinib Mesylate